Le Lézard
Classified in: Health, Business
Subject: FNC

HealthEdge Completes Investment in Anodyne


TAMPA, Fla., April 29, 2022 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge"), a healthcare focused private equity fund, announced today that it has completed an investment in Anodyne, LLC ("Anodyne"), a leading provider of lifestyle-oriented clinical footwear solutions most commonly prescribed for diabetic patients.

HealthEdge completes investment in Anodyne, leading provider of lifestyle-oriented clinical footwear for diabetics

Anodyne was founded in 2015 by a group of industry executives who set out to reimagine the diabetic footwear market and establish a new, leading brand?one that would offer patients a variety of modern and stylish shoe selections and suppliers an unmatched service experience. Over the past seven years, the market has responded enthusiastically to Anodyne's innovative and contemporary approach.

Today, Anodyne's shoes are known for their market-leading style, function, and comfort. Anodyne supports its diabetic shoe offering with a line of shoe inserts and custom orthotics, which are manufactured at the company's in-house fabrication facility in Milwaukee.

Diabetics are at a significantly increased risk for diabetic foot ulcers, which can often lead to lower limb amputations and even death. The use of diabetic footwear has been shown to reduce the incidence of diabetic foot ulcers, but a lack of contemporary shoe selections has historically resulted in low patient adherence. Anodyne's improved shoe designs are addressing this issue by providing diabetic patients with footwear options that appeal to their individual comfort needs and style desires.

HealthEdge Partner Scott Heberlein commented, "Diabetic foot complications represent a significant medical risk to the growing diabetic population. A risk that can be drastically mitigated by the proper application of therapeutic footwear. It is exciting to see how a relatively low-cost intervention can have such a meaningful impact on improved patient outcomes. We look forward to partnering with the Anodyne team to expand the reach of this important preventative product." Bobby Kanter, Anodyne's Co-Founder and CEO, added, "Anodyne was founded with a vision of being the absolute best. We've been relentless in our pursuit to offer at-risk, diabetic patients the most stylish and comfortable footwear available, and offer footcare providers the utmost level of service and support in fitting and dispensing these limb-saving devices. The reception from our customers has been overwhelmingly positive and we are looking forward to accelerating the growth of our brand with HealthEdge's support."

ABOUT HEALTHEDGE
HealthEdge Investment Partners, LLC is an operating-oriented private equity firm founded in 2005 that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge's partners have more than 100 years of combined operating experience in healthcare as CEOs and investors. For more information on HealthEdge, please visit healthedgepartners.com.

ABOUT ANODYNE
Anodyne is a leading brand and foremost innovator of clinical footwear solutions aimed at the growing diabetic population. For more information on Anodyne, please visit www.anodyneshoes.com.

Media Contact:
Jessica Hudson,
[email protected]

SOURCE HealthEdge Investment Partners, LLC


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: